Targeting of Proteins into Peroxisomes
将蛋白质靶向过氧化物酶体
基本信息
- 批准号:9788413
- 负责人:
- 金额:$ 51.2万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2018
- 资助国家:美国
- 起止时间:2018-09-20 至 2022-08-31
- 项目状态:已结题
- 来源:
- 关键词:ATP phosphohydrolaseAntiviral AgentsAutophagocytosisBiochemicalBiogenesisCellular MembraneCytosolDiseaseDockingEndoplasmic ReticulumFirefly LuciferasesFundingFutureGenesGeneticGleanGlutathioneGrantGrowthHealthHomeostasisHumanHuman DevelopmentImpairmentIn VitroIntracellular MembranesInvestigationKnowledgeMammalian CellMammalsMembraneMembrane ProteinsMetabolismMitochondriaNitrogenOrganellesOrganismOxidation-ReductionOxygenPeripheralPhysiologicalPichiaPlantsPlayPopulationProtein ImportProteinsQuality ControlReactionReceptor SignalingRecyclingRegulationReportingRoleSaccharomyces cerevisiaeSignal TransductionSiteSorting - Cell MovementStressSuggestionSystemTechniquesTertiary Protein StructureUbiquitinVesicleWorkYeast Model SystemYeastsbasefatty acid oxidationinnovationinsightinterestmannovelperoxisomereceptor
项目摘要
Peroxisomes are essential subcellular organelles that play crucial roles in the oxidation of fatty-acids and
homeostasis of glutathione, as well as reactive oxygen and nitrogen species (ROS and RNS, respectively). They
play critical roles in the regulation of intracellular redox states and antiviral signaling, as well as cellular
differentiation and metabolism, and their impairment causes many debilitating, and often fatal, human
peroxisome biogenesis disorders (PBDs). Their biogenesis is orchestrated by 36 PEX genes, encoding peroxins,
involved in the biogenesis of peroxisomal membrane and matrix proteins, as well as in the control of organelle
size, number and inheritance. Their biogenesis has been studied in many organisms from yeast to plants and
mammals, and more than 15 peroxins and their modes of action are conserved from yeast to man. While much
has been learned about the biogenesis of peroxisomal matrix and membrane proteins to pre-existing
peroxisomes, far less is known about how this organelle is generated de novo from other endogenous
membranes. Such an ability to generate new peroxisomes de novo is obviously relevant under conditions where
peroxisome biogenesis is impaired (e.g. human PBDs), or under conditions of stress (e.g. ROS) when
peroxisomes are turned over by autophagy (pexophagy). Indeed, any disorders associated with imbalanced
peroxisome homeostasis can be corrected, in principle, by manipulating either peroxisome biogenesis or its
turnover, as we have shown. Such a global understanding of the mechanisms involved in peroxisome
homeostasis is the long-term interest of my lab.
Over almost 3 decades, we exploited the yeast, Pichia pastoris, to provide many major insights into our
knowledge of peroxisome biogenesis and turnover. This proposal focuses on gleaning a deeper understanding
of the proteins involved in the intra-ER sorting and budding of peroxisomal membrane proteins (PMPs) to a pre-
peroxisomal exit site on the ER (pER) from where at least two type of pre-peroxisomal vesicles (ppVs) bud to
ultimately generate peroxisomes, either by fusion with pre-existing peroxisomes or anew when peroxisomes are
absent. Budding of ppVs is conserved between yeast and mammals and several proteins we will study have
counterparts involved in human health. There are also reports of ppVs derived from mitochondria contributing to
peroxisome biogenesis. Our approach is based on the use of novel genetic and biochemical strategies, including
ppV purification and characterization, in vitro budding reactions and the use of innovative techniques to follow
what these novel proteins do, where they act, who they interact with and how they function. The Aims are:
Aim 1 - Isolation and characterization of the ATPase/s and other proteins involved in ppV budding.
Aim 2 – How do Pex25 and Pex36 act in stimulating intra-ER sorting and budding of Pex2 and other RING-
domain peroxins?
Aim 3 – Does ppV budding occur from yeast mitochondria and what is its physiological relevance?!
过氧化物酶体是重要的亚细胞器,在脂肪酸的氧化中起关键作用,
谷胱甘肽的稳态,以及活性氧和氮物种(ROS和RNS,分别)。他们
在调节细胞内氧化还原状态和抗病毒信号传导以及细胞内
分化和代谢,以及他们的损害造成许多衰弱,往往是致命的,人类
过氧化物酶体生物发生障碍(PBD)。它们的生物发生由36个PEX基因协调,编码过氧化物酶,
参与过氧化物酶体膜和基质蛋白的生物发生,以及细胞器的控制
大小、数量和继承。它们的生物起源已在从酵母到植物的许多生物体中进行了研究,
从酵母到人类,超过15种过氧化物及其作用方式是保守的。
已经了解到过氧化物酶体基质和膜蛋白的生物发生,
过氧化物酶体,远不知道这个细胞器是如何产生从头从其他内源性
膜。这种从头产生新过氧化物酶体的能力显然与以下条件相关:
过氧化物酶体生物合成受损(例如人PBD),或在应激条件下(例如ROS),
过氧化物酶体通过自噬(pexophagy)被翻转。事实上,任何与不平衡有关的疾病
原则上,可以通过操纵过氧化物酶体生物发生或其代谢产物来纠正过氧化物酶体的稳态。
正如我们所展示的那样,营业额。这种对过氧化物酶体机制的全面理解
自我平衡是我实验室的长期目标
在近30年的时间里,我们利用酵母,巴斯德毕赤酵母,提供了许多重要的见解,
过氧化物酶体生物发生和周转知识。这项建议的重点是收集更深入的了解
的蛋白质参与内质网内分选和出芽的过氧化物酶体膜蛋白(PMP)的前,
ER上的过氧化物酶体出口位点(pER),至少有两种类型的前过氧化物酶体囊泡(PPV)从此处出芽,
最终产生过氧化物酶体,或者通过与预先存在的过氧化物酶体融合,或者当过氧化物酶体
无托叶PPV的出芽在酵母和哺乳动物之间是保守的,我们将研究的几种蛋白质具有
参与人类健康的同行。也有来自线粒体的ppV有助于
过氧化物酶体生物发生我们的方法是基于使用新的遗传和生化策略,包括
PPV的纯化和表征,体外出芽反应和使用创新技术,以遵循
这些新的蛋白质做什么,它们在哪里起作用,它们与谁相互作用以及它们如何发挥作用。目标是:
目的1 -分离和表征参与PPV出芽的ATPase/s和其他蛋白。
目的2 -Pex 25和Pex 36如何在刺激ER内分选和Pex 2和其他RING的出芽中起作用。
域过氧化物酶?
目的3 -PPV出芽是否发生在酵母线粒体中,其生理相关性是什么?!
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Suresh Subramani其他文献
Suresh Subramani的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Suresh Subramani', 18)}}的其他基金
相似海外基金
Development of a new generation of antiviral agents that are effective against drug-resistant viruses and prevent serious illness and sequelae.
开发新一代抗病毒药物,可有效对抗耐药病毒并预防严重疾病和后遗症。
- 批准号:
23K18186 - 财政年份:2023
- 资助金额:
$ 51.2万 - 项目类别:
Grant-in-Aid for Challenging Research (Exploratory)
A versatile structure-based therapeutic platform for development of VHH-based antitoxin and antiviral agents
一个多功能的基于结构的治疗平台,用于开发基于 VHH 的抗毒素和抗病毒药物
- 批准号:
10560883 - 财政年份:2023
- 资助金额:
$ 51.2万 - 项目类别:
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
用于发现新型抗病毒药物的基因编码双环肽库
- 批准号:
10730692 - 财政年份:2021
- 资助金额:
$ 51.2万 - 项目类别:
Design and synthesis of nucleosides to develop antiviral agents and oligonucleotide therapeutics
设计和合成核苷以开发抗病毒药物和寡核苷酸疗法
- 批准号:
21K06459 - 财政年份:2021
- 资助金额:
$ 51.2万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
用于发现新型抗病毒药物的基因编码双环肽库
- 批准号:
10189880 - 财政年份:2021
- 资助金额:
$ 51.2万 - 项目类别:
Computer-aided identification and synthesis of novel broad-spectrum antiviral agents
新型广谱抗病毒药物的计算机辅助鉴定和合成
- 批准号:
2404261 - 财政年份:2020
- 资助金额:
$ 51.2万 - 项目类别:
Studentship
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
- 批准号:
10222540 - 财政年份:2020
- 资助金额:
$ 51.2万 - 项目类别:
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
- 批准号:
10669717 - 财政年份:2020
- 资助金额:
$ 51.2万 - 项目类别:
Association between sedentary lifestyle and liver cancer development in hepatitis C patients treated with direct-acting antiviral agents
接受直接抗病毒药物治疗的丙型肝炎患者久坐的生活方式与肝癌发展之间的关系
- 批准号:
20K10713 - 财政年份:2020
- 资助金额:
$ 51.2万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
- 批准号:
10174522 - 财政年份:2020
- 资助金额:
$ 51.2万 - 项目类别:














{{item.name}}会员




